A short overview of CRISPR-Cas technology and its application in viral disease control

A short overview of CRISPR-Cas technology and its application in viral disease control.

Full text not available from this repository.
Item Type: Review
Status: Published
Official URL: https://doi.org/10.1007/s11248-021-00247-w
Journal or Publication Title: Transgenic Research
Volume: 30
Number: 3
Page Range: pp. 221-238
Date: 2021
Divisions: Directed Evolution
Depositing User: General Admin
Identification Number: 10.1007/s11248-021-00247-w
ISSN: 0962-8819
Date Deposited: 10 Jun 2021 05:49
Abstract:

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs) together with CRISPR-associated (Cas) proteins have catalysed a revolution in genetic engineering. Native CRISPR-Cas systems exist in many bacteria and archaea where they provide an adaptive immune response through sequence-specific degradation of an invading pathogen's genome. This system has been reconfigured for use in genome editing, drug development, gene expression regulation, diagnostics, the prevention and treatment of cancers, and the treatment of genetic and infectious diseases. In recent years, CRISPR-Cas systems have been used in the diagnosis and control of viral diseases, for example, CRISPR-Cas12/13 coupled with new amplification techniques to improve the specificity of sequence-specific fluorescent probe detection. Importantly, CRISPR applications are both sensitive and specific and usually only require commonly available lab equipment. Unlike the canonical Cas9 which is guided to double-stranded DNA sites of interest, Cas13 systems target RNA sequences and thus can be employed in strategies directed against RNA viruses or for transcriptional silencing. Many challenges remain for these approach, including issues with specificity and the requirement for better mammalian delivery systems. In this review, we summarize the applications of CRISPR-Cas systems in controlling mammalian viral infections. Following necessary improvements, it is expected that CRISPR-Cas systems will be used effectively for such applications in the future.

Creators:
Creators
Email
Ghorbani, Abozar
UNSPECIFIED
Hadifar, Shima
UNSPECIFIED
Salari, Roya
UNSPECIFIED
Izadpanah, Keramatollah
UNSPECIFIED
Burmistrz, Michal
UNSPECIFIED
Afsharifar, Alireza
UNSPECIFIED
Eskandari, Mohammad Hadi
UNSPECIFIED
Niazi, Ali
UNSPECIFIED
Denes, Christopher E.
UNSPECIFIED
Neely, G. Gregory
UNSPECIFIED
Last Modified: 10 Jun 2021 05:49
URI: https://eprints.centenary.org.au/id/eprint/990

Actions (login required)

View Item View Item